ONEighty C Technologies Corporation Presentation

WAVEPulse™ Sterilization

ONEighty C Technologies

ONEighty C Technologies Corporation believes that this presentation contains forward-looking statements. Such forward-looking statements are based on

management’s current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. The

Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

Problem: Sterilizing Medical Devices

3

CRE-infected endoscope tips led to deaths at UCLA Medical

Center

Blood, bone, flesh and rust inside instruments

More than 1.6 million endoscopy procedures annually

4

Deadly bacteria on medical scopes trigger

infections

Deadly superbug-related scopes sold without FDA approval?

FDA Issues Warning on Medical Device After Superbug Outbreak

Agency Says Type of Endoscope Is Hard

to Clean, Allowing Deadly Bacteria to Be

Transmitted

Deadly Superbug CRE Linked To 2 Deaths

In Los Angeles

Increasing Complexity of Surgical Equipment

5

Traditional Surgical Devices

Simple tools Temperature tolerant Metal Smooth surfaces Come apart easily for cleaning

Complex, minimally invasive devices Temperature sensitive Rubber, plastic, metals, adhesives Articulating parts Long lumens

Advanced Surgical Devices

Current Technology Does Not Sterilize All Infectious Organisms

6

Susceptible

Infectious Organism Example Current Technology

Lipid or medium-sized viruses HIV, Herpes, Hepatitis B

Disinfection - Low Vegetative bacteria S. aureus, P. aeruginosa

Fungi Aspergillus, Candida Disinfection - Intermediate Nonlipid or small viruses Polio, Coxsackie

Mycobacteria M. tuberculosis Disinfection - High

Coccidia Cryptoporidum Sterilization

Bacterial spores Bacillus atrophaeus

Prions Creutzfeldt-Jakob Disease Sterilization without prion destruction

Resistant

Guideline for Disinfection and Sterilization in Healthcare Facilities, CDC 2008

Ste

riliz

atio

n

Emerging Infectious Risks

7

Emerging Risks Impact

CRE Carbapenem-resistant Enterobacteriaceae

May contribute to death in 50% of infected patients (CDC)

C. diff Clostridium difficile

Est. 29,000 deaths in USA

MRSA Methicillin-resistant Staphylococcus aureus

MRSA-related hospitalization >11 / 100,000 patients

Prions Not destroyed by existing sterilization processes

Greatest risk in brain, spinal and eye surgeries >100,000 /year

Prions: Emerging Infectious Risk

8

Medtronic Devices May Have Exposed Patients to Creutzfeldt-

Jakob Disease

N.H. patients possibly

exposed to fatal brain disease

30K in U.K. Could Carry

Human Form of Mad Cow

Disease

• Not destroyed by any existing sterilization methods

Severe Patient Infection and Death Risks

9

Unmet Needs • Non-sterility of reprocessed

medical devices due to residual pathogens, bodily fluids or tissues

• Limited efficacy of current low-temperature sterilization processes

• Inability to destroy extremely stable proteins (e.g. prions)

High Risk and Fatal Consequences

• Recent deaths from CRE or

C.diff - infected endoscopes

• Severe infection or death from MRSA and other bio-pathogens

• Death from incurable Creutzfeldt-Jakob Disease (Mad Cow)

WAVEPulse™ Sterilization Process

10

• New technology • Combines microwave, heat

and water • Fragments DNA/RNA and

proteins • Raises standards to

Sterilization

WAVEPulse™ High Performance Sterilization

11

High temperature SAL 10-4 to 10-6

Existing processes

On-

site

Ste

riliz

atio

n

Proprietary Processes, Safe, Effective

WAVEPulse™ Heat-sensitive or

heat-tolerant devices

WAVEPulse™ Differentiation Characteristics

12

• Faster, cheaper, smarter • Improves patient safety • Non-toxic process • Sterilizes, de-immunizes, de-toxifies • Low-temperature sterilization • Unequalled 10-10 SAL • Compliant data tracking

WAVEPulse™: New Standard Of Sterilization

13

Sterility Assurance Level System Pathogen

Sample Surviving

Pathogens

10-4 Autoclave 1 billion 100,000

10-10 WAVEPulse™ 1 billion 0.1

Highly-disinfected

Sterilization: Autoclave 10-4

10-10

WAVEPulse™ Disinfected

Standard Continuum

$1.7B Addressable Market Opportunity For

Heat-Sensitive Device Sterilization In US Alone

• 11% CAGR for heat-sensitive sterilization equipment market

• 20-25% of medical instruments require low temperature sterilization, up from 10-15% 10 years ago

• Growth drivers include reprocessing of devices or instruments that are indicated and labeled for multi-use

• WAVEPulse™ platform aligns with increasing cost reduction pressure

14

WAVEPulse™ Milestones

15

Achieved: • 10-10 SAL • Anthrax Sterilization (spore of greatest resistance) • 80oC sterilization • Prion destruction

Near-Term Goals: • Next generation prototype • 60oC sterilization • Optimized microwave function • Combined sterilization, de-immunization, detoxification • Biofilm penetration

Collaboration Goals: • Develop improved end-user experience • Beta-testing

World Class Centers of Healthcare Innovation

16

Leadership Team

17

Eric Walters, CEO and Co-Founder EVP/CFO of PolyMedica [NASDAQ:PLMD]. Grew medical device revenue

from $1M to $350M. Company was later acquired for $1.5B cash. Raised >$100M capital.

Michael Fritz, BOD Member Founder, Plexius Consulting Principal, IBM Global Services and AT Kearney Consulting

Advisory Expertise Microbiology, physics, market research, independent laboratory validation,

production design, CAD/CAM and specialty manufacturing, FDA regulatory, IP

Corporate Partners Product Resources Toxikon Corporation

Unmatched Performance Characteristics = Value

Proposition

Entry of novel, non-toxic process into healthcare market

Sterilization of reprocessed medical devices due to residual pathogens, bodily fluids or tissues

Prion destruction

Higher standard for low-temperature sterilization

WAVEPulse ™ fragments DNA and destroys pathogens

Unequalled10-10 Sterility Assurance Level exceeds existing processes

Fully-owned patents

ONEighty C Technologies

18

WAVEPulse™ Sterilization

Contact information

Eric G. Walters

CEO and Co-Founder

(978) 505-7339

eric.walters@oneightyc.com

www.oneightyc.com

19

ONEighty C Technologies

WAVEPulse™ Sterilization